BR112021025944A2 - Sais de um composto, formas cristalinas dos sais e método de preparação e uso dos mesmos - Google Patents
Sais de um composto, formas cristalinas dos sais e método de preparação e uso dos mesmosInfo
- Publication number
- BR112021025944A2 BR112021025944A2 BR112021025944A BR112021025944A BR112021025944A2 BR 112021025944 A2 BR112021025944 A2 BR 112021025944A2 BR 112021025944 A BR112021025944 A BR 112021025944A BR 112021025944 A BR112021025944 A BR 112021025944A BR 112021025944 A2 BR112021025944 A2 BR 112021025944A2
- Authority
- BR
- Brazil
- Prior art keywords
- salts
- crystalline forms
- fluoro
- compound
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910542355 | 2019-06-21 | ||
| PCT/CN2020/097482 WO2020253875A1 (zh) | 2019-06-21 | 2020-06-22 | 一种化合物的盐、其晶型以及制备方法与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021025944A2 true BR112021025944A2 (pt) | 2022-02-08 |
Family
ID=74040655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021025944A BR112021025944A2 (pt) | 2019-06-21 | 2020-06-22 | Sais de um composto, formas cristalinas dos sais e método de preparação e uso dos mesmos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220168302A1 (enExample) |
| EP (1) | EP3988546A4 (enExample) |
| JP (1) | JP2022538076A (enExample) |
| KR (1) | KR20220041090A (enExample) |
| CN (1) | CN115708409A (enExample) |
| AR (1) | AR119184A1 (enExample) |
| AU (1) | AU2020296048A1 (enExample) |
| BR (1) | BR112021025944A2 (enExample) |
| CA (1) | CA3144546A1 (enExample) |
| CL (1) | CL2021003438A1 (enExample) |
| CO (1) | CO2022000502A2 (enExample) |
| IL (1) | IL289231A (enExample) |
| MX (1) | MX2022000051A (enExample) |
| PH (1) | PH12021553151A1 (enExample) |
| WO (1) | WO2020253875A1 (enExample) |
| ZA (1) | ZA202200964B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022042738A1 (zh) * | 2020-08-31 | 2022-03-03 | 甘李药业股份有限公司 | 一种含cdk4/6抑制剂的药物组合物 |
| US20250332167A1 (en) * | 2021-05-17 | 2025-10-30 | Gan & Lee Pharmaceuticals Co., Ltd. | Pharmaceutical use of cdk 4/6 inhibitor |
| EP4696689A1 (en) * | 2023-04-04 | 2026-02-18 | Suzhou Kintor Pharmaceuticals, Inc. | Salt form and crystal form of chiral heterocyclic compound having hedgehog pathway antagonist activity |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK9742002A3 (en) * | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| CN106810536A (zh) * | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
-
2020
- 2020-06-18 AR ARP200101717A patent/AR119184A1/es not_active Application Discontinuation
- 2020-06-22 WO PCT/CN2020/097482 patent/WO2020253875A1/zh not_active Ceased
- 2020-06-22 EP EP20827805.1A patent/EP3988546A4/en not_active Withdrawn
- 2020-06-22 PH PH1/2021/553151A patent/PH12021553151A1/en unknown
- 2020-06-22 AU AU2020296048A patent/AU2020296048A1/en not_active Withdrawn
- 2020-06-22 KR KR1020227002390A patent/KR20220041090A/ko not_active Withdrawn
- 2020-06-22 CA CA3144546A patent/CA3144546A1/en active Pending
- 2020-06-22 JP JP2021576253A patent/JP2022538076A/ja active Pending
- 2020-06-22 US US17/596,721 patent/US20220168302A1/en not_active Abandoned
- 2020-06-22 MX MX2022000051A patent/MX2022000051A/es unknown
- 2020-06-22 BR BR112021025944A patent/BR112021025944A2/pt unknown
- 2020-06-22 CN CN202080045649.9A patent/CN115708409A/zh active Pending
-
2021
- 2021-12-21 IL IL289231A patent/IL289231A/en unknown
- 2021-12-21 CL CL2021003438A patent/CL2021003438A1/es unknown
-
2022
- 2022-01-20 ZA ZA2022/00964A patent/ZA202200964B/en unknown
- 2022-01-21 CO CONC2022/0000502A patent/CO2022000502A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3144546A1 (en) | 2020-12-24 |
| EP3988546A4 (en) | 2023-05-17 |
| EP3988546A1 (en) | 2022-04-27 |
| AR119184A1 (es) | 2021-12-01 |
| KR20220041090A (ko) | 2022-03-31 |
| MX2022000051A (es) | 2022-05-24 |
| CO2022000502A2 (es) | 2022-01-28 |
| US20220168302A1 (en) | 2022-06-02 |
| AU2020296048A1 (en) | 2022-02-10 |
| CN115708409A (zh) | 2023-02-21 |
| PH12021553151A1 (en) | 2022-07-25 |
| WO2020253875A1 (zh) | 2020-12-24 |
| CL2021003438A1 (es) | 2022-09-30 |
| JP2022538076A (ja) | 2022-08-31 |
| IL289231A (en) | 2022-02-01 |
| ZA202200964B (en) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022008717A2 (pt) | Composto de fórmula, um isômero óptico, uma forma cristalina ou um sal farmaceuticamente aceitável ou éster deste, inibidor de aurora quinase, composição farmacêutica, e uso do composto | |
| MX2022005951A (es) | Compuestos de pirrolotriazina que actuan como inhibidor de mnk. | |
| Riding et al. | A review of the chronostratigraphical ages of Middle Triassic to Late Jurassic dinoflagellate cyst biozones of the North West Shelf of Australia | |
| PH12016000029B1 (en) | A novel crystalline form of a benzimidazole derivative and a preparation method thereof | |
| BR112022016072A2 (pt) | Compostos moduladores de gcn2, sal farmaceuticamente aceitável, seus usos, e composição farmacêutica | |
| BR112018000687A2 (pt) | composto, composição e mistura herbicida e métodos para o controle do crescimento da vegetação indesejada | |
| BR112017021859A2 (pt) | ?composto, composição e mistura herbicida e método para o controle do crescimento de vegetação indesejada? | |
| WO2009139576A3 (ko) | 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상세포 성장 질환의 예방 및 치료용 약학적 조성물 | |
| AU2017285758A1 (en) | Method for improving salt tolerance of plant | |
| UA106057C2 (uk) | Спосіб одержання сполук дигідроінденаміду, фармацевтична композиція, що містить дані сполуки, та їх застосування як інгібітора протеїнкінази | |
| EA201992501A1 (ru) | Соль соединения производного аминопиридина, ее кристаллическая форма и способ получения | |
| WO2005016261A3 (en) | Aripiprazole and haloperidol pamoate salts | |
| CO2022000502A2 (es) | Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas | |
| BR112018001964A2 (pt) | composto, composição herbicida, mistura herbicida e método para o controle do crescimento de vegetação | |
| EA201990688A1 (ru) | Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение | |
| MY199042A (en) | Aminopyrimidine compound, preparation method therefor and use thereof | |
| HK1222396A1 (zh) | 作为选择性蛋白质激酶抑制剂之苯并咪唑衍生物 | |
| WO2016025933A3 (en) | Substituted polycyclic antibacterial compounds | |
| BR112014001083A8 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto | |
| BR112021024300A2 (pt) | Formas de sais cristalinas de um inibidor de quinase | |
| EA201691139A1 (ru) | Фармацевтическая композиция, содержащая соединение пиридиламиноуксусной кислоты и полиоксиэтиленовое касторовое масло | |
| AU2019375825A8 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| Van der Heijden et al. | Trophic importance of microphytobenthos and bacteria to meiofauna in soft-bottom intertidal habitats: A combined trophic marker approach | |
| MY198008A (en) | Crystal of benzofuran derivative free base and preparation method | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |